Related Experiment Video

Updated: Aug 14, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Investor initiatives program: Public-private partnerships to expedite commercialization for NCI-funded small business

Brittany Connors1, Xing-Jian Lou1, Ashim Subedee1

  • 1National Cancer Institute Small Business Innovation Research Development Center, Rockville, Maryland, USA.

Clinical and Translational Science
|August 13, 2021
PubMed

Insights

The National Cancer Institute

Area of Science:

  • Biotechnology
  • Cancer Research
  • Small Business Development

Background:

  • Federal funding is crucial but often insufficient for early-stage cancer technology commercialization.
  • Life science startups require follow-on capital and resources to bring innovations to patients.
  • Startups often struggle to secure funding due to limited access to investors and effective pitching skills.

Purpose of the Study:

  • To evaluate the effectiveness of the National Cancer Institute's Small Business Innovation Research Development Center (NCI SBIR) Investor Initiatives program.
  • To demonstrate how public-private partnerships can assist NCI-funded companies in securing follow-on funding.
  • To accelerate the translation of cancer research into clinical practice.

Main Methods:

  • The NCI SBIR established the Investor Initiatives program in 2015 to connect small businesses with investors and partners.
  • The program provides business-focused reviews and pitch coaching.
  • Supported 117 companies from 2016-2019, facilitating participation in 27 investor showcase events.

Main Results:

  • The Investor Initiatives program facilitated connections between NCI-funded companies and private investors.
  • Surveys indicated the program contributed to 32 completed deals as of April 29, 2020.
  • The program successfully assisted portfolio companies in raising crucial follow-on funding.

Conclusions:

  • The NCI SBIR Investor Initiatives program effectively leverages public-private partnerships.
  • The program demonstrates a successful model for accelerating cancer technology commercialization.
  • Federal initiatives can play a vital role in bridging the funding gap for life science startups.

More Related Videos

PIP-on-a-chip: A Label-free Study of Protein-phosphoinositide Interactions10:58

PIP-on-a-chip: A Label-free Study of Protein-phosphoinositide Interactions

Published on: July 27, 2017

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Related Concept Videos

Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
iChip01:24

iChip

The cultivation of environmental microorganisms has long been hindered by the inability to replicate complex native conditions in vitro. The isolation chip (iChip) addresses this limitation by facilitating the growth of previously uncultivable microorganisms through in situ incubation. Designed for high-throughput microbial cultivation, the iChip comprises hundreds of microchambers, each capable of housing a single microbial cell. These microchambers are loaded with a mixture of molten agar and...